Navigation Links
VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
Date:12/29/2009

in the United States and many developed countries. I wish to thank all of the VIVUS employees, contractors and advisors who contributed to the program and made this on-time filing possible."

Previously reported highlights from the two 56-week EQUIP and CONQUER studies comprising more than 3,750 patients include:

  • Weight loss of up to 14.7% (37 lbs) achieved by patients treated with Qnexa for 56 weeks in the EQUIP study;
  • Statistically significant improvements in cardiovascular, metabolic and inflammatory risk factors among patients treated with Qnexa;
  • FDA efficacy benchmarks for weight loss agents were exceeded at all three doses of Qnexa tested in the clinical program;
  • Completion rates up to 69% were statistically significantly higher than placebo at all three doses of Qnexa, indicating favorable tolerability; and
  • Across both 56-week studies, the most commonly reported side effects were dry mouth, tingling and constipation.

About the Phase 3 Program

The phase 3 clinical program, evaluating Qnexa in more than 4,500 patients, was designed under a Special Protocol Assessment with the U.S. FDA and consists of three trials: EQUATE (OB-301), EQUIP (OB-302) and CONQUER (OB-303). The EQUATE study was a 28-week randomized, double-blind, placebo-controlled, 7-arm, prospective trial with subjects randomized to receive once-a-day treatment with mid- or full-dose Qnexa, the respective constituents, or placebo. The average baseline BMI of the study population was 36.3 kg/m(2) with an average baseline weight of 223 pounds. The EQUIP and CONQUER studies were 56-week, randomized, double-blind, placebo-controlled, 3-arm, prospective trials with patients randomized to receive once-a-day treatment with low-, mid-, or full-dose Qnexa, or placebo. In EQUIP, the average baseline BMI of the study population was 42.1 kg/m(2) with an av
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
2. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
3. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
4. VIVUS Announces Promotion of Peter Tam to President
5. VIVUS to Present at Lazard Capital Markets Healthcare Conference
6. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
7. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
8. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
9. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
10. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
11. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 A German Diabetes ... L. reuteri probiotic enriches human gut microbiota ... insulin secretion.  The study involved daily administration of Nutraceutix,s ... tablets using the patented BIO- tract ® ... stomach acid on their way to the intestinal tract. ...
(Date:7/28/2015)... , July 28, 2015  SeraCare Life Sciences, ... manufacturers, announced today at the American Association of ... a licensing agreement with the University of California, ... 21 (T21), Trisomy 18 (T18) and Trisomy 13 ... for creating "patient-like" reference materials for Non-Invasive Prenatal ...
(Date:7/28/2015)... -- The Physician-Patient Alliance for Health & Safety (PPAHS) ... Your Hospital Stay ." "Help us ensure ... these patients went home from hospital," said Michael ... to the patient stories presented at the ... Continuous Monitoring of Patients on Opioids (shown above). ...
Breaking Medicine Technology:Nutraceutix's L. reuteri Probiotic Clinically Proven to Modulate Gut Insulin Metabolism 2SeraCare Life Sciences Signs License Agreement with UCSF and Announces Early Access Program for Development of Aneuploidy Reference Materials 2SeraCare Life Sciences Signs License Agreement with UCSF and Announces Early Access Program for Development of Aneuploidy Reference Materials 3Surviving Your Hospital Stay: Physician-Patient Alliance for Health & Safety Launches Fundraising for Patient Safety 2
... Verathon Inc. is pleased to announce that ... manufacturing facility has made enhancements to GlideScope GVL®, ... to better withstand more rigorous vaporized hydrogen peroxide ... disinfection and sterilization systems in the market prompted ...
... /PRNewswire-Asia/ -- Tongjitang Chinese Medicines Company ("Tongjitang" or the ... has called an extraordinary general meeting of shareholders (the ... on Thursday, March 31, 2011, at the Company,s offices ... 1019 Nanhai Avenue, Nanshan District, Shenzhen, 518067 Guangdong Province, ...
Cached Medicine Technology:Verathon Enhances GlideScope® Video Laryngoscopes to Accommodate Newer Vaporized Hydrogen Peroxide Disinfection and Sterilization Systems 2Tongjitang Chinese Medicines Company Announces Extraordinary General Meeting of Shareholders 2Tongjitang Chinese Medicines Company Announces Extraordinary General Meeting of Shareholders 3
(Date:7/29/2015)... ... July 29, 2015 , ... For the second year in a ... the list of the 50 fastest growing companies in Jacksonville. This annual list is ... On July 16th, a team of Vast Bridges staffers were on hand to receive ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... CanAm Enterprises, ... by USCIS over the past month! I-829 approvals have been granted to investors in ... Los Angeles, the Kimpton Lafayette Hotel project in Philadelphia, and the Valley Forge Convention ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... A June ... Checked for Skin Cancer ," discussed the importance of having regular skin cancer screenings ... person has excessive exposure to ultraviolet rays. When caught early, skin cancer is rarely ...
(Date:7/29/2015)... ... July 29, 2015 , ... Several years ago, in order to be ... Little City took a proactive stance and began planning the Children’s Village consisting of ... valuable support to building the third home. , “We are very pleased to have ...
(Date:7/29/2015)... ... July 29, 2015 , ... Toronto ... the late 1970s, Dr. Cottrell has been making predictions about the economy, politics, ... documents many of these prognostications. He warns that extreme weather conditions and increased ...
Breaking Medicine News(10 mins):Health News:Vast Bridges Continues Its Swift Growth 2Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 2Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 3Health News:Get Checked for Skin Cancer Early and Often 2Health News:Get Checked for Skin Cancer Early and Often 3Health News:Little City Receives $500,000 Matching Grant from The Coleman Foundation 2Health News:Little City Receives $500,000 Matching Grant from The Coleman Foundation 3Health News:Author Warns Public to Prepare for Imminent Environmental Disaster 2
... LCA-Vision Inc. (Nasdaq: LCAV ), ... Lasik Plus (R) brand, today announced that members of its ... Annual Institutional Investors Conference on Monday, March 9, 2009 at ... at The JW Marriott Grande Lakes Hotel in Orlando, Fla. ...
... /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), ... that the Company has amended the maturity date ... Valens U.S. (formerly Laurus Master Funds). , On ... a near-term extension of this facility, originally scheduled ...
... restructure debt -MCLEAN, Va., March 2 Sunrise Senior Living, ... and operating data for the fourth quarter and the full-year ... Monday, March 2, 2009, at 9:00 a.m. ET, to discuss ... life for seniors has been Sunrise,s mission since 1981, and ...
... Cardiac Science Corporation (Nasdaq: CSCX ), ... and informatics products, announced today that it will release ... 12, 2009 after the market close. The Company has ... 4:30 p.m. Eastern Time. During the call, Cardiac ...
... March 2 Alexza Pharmaceuticals, Inc. (Nasdaq: ... Noymer, PhD has been promoted to Vice President, ... position, he will have oversight responsibilities for device ... technology programs.Dr. Noymer joined Alexza in 2006 and ...
... APA,s Psychologically Healthy Workplace Awards, Ten Honored for ... of the economy can be felt across all ... during tough economic times reap rewards for employer ... (APA) at its Psychologically Healthy Workplace Awards ceremony ...
Cached Medicine News:Health News:Bioniche Revolving Credit Facility Maturity Date Amended 2Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 2Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 3Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 4Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 5Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 6Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 7Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 8Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 9Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 10Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 11Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 12Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 13Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 14Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 15Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 16Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 17Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 18Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 19Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 20Health News:Cardiac Science Schedules Fourth Quarter Earnings Release and Announces Conference Call 2Health News:Alexza Pharmaceuticals Promotes Peter D. Noymer, PhD to Vice President, Product R&D 2Health News:Alexza Pharmaceuticals Promotes Peter D. Noymer, PhD to Vice President, Product R&D 3Health News:Top Employers Find That in Tough Economic Times, a Healthy, Productive Workplace is More Important Than Ever 2Health News:Top Employers Find That in Tough Economic Times, a Healthy, Productive Workplace is More Important Than Ever 3Health News:Top Employers Find That in Tough Economic Times, a Healthy, Productive Workplace is More Important Than Ever 4
Colour video monitors....
Camera and light source in one compact "Plug-and-Play" device....
... system of choice for customers performing routine ... throughput laboratories in more than 50 countries ... Behring is pleased to announce the placement ... ,The customer centered development process of the ...
... The original ultrasonic ... technology, having an 11-year ... a Large array of ... and femoral applications, cemented ...
Medicine Products: